UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION
                           WASHINGTON, D. C. 20549


                                 FORM 10-QSB



              QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE
                       SECURITIES EXCHANGE ACT OF 1934



                           FOR THE QUARTER ENDED JUNE 30, 1999
                             COMMISSION FILE NUMBER: 0-24378


                            FIRST SCIENTIFIC, INC.
      (EXACT NAME OF SMALL BUSINESS ISSUER AS SPECIFIED IN ITS CHARTER)


              DELAWARE                               33-0611745
     ----------------------------        --------------------------------
     (STATE OR OTHER JURISDICTION        (IRS EMPLOYER IDENTIFICATION NO.)
   OF INCORPORATION OR ORGANIZATION)

               1877 WEST 2800 SOUTH, SUITE 200, OGDEN, UTAH 84401
               --------------------------------------------------
                  (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

   REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (801) 393-5781


      Check whether the issuer (1) filed all reports required to be
filed by Sections 13 or 15(d) of the Exchange Act during the past 12
months (or for shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements for
the past 90 days.

      YES        X              NO


These were 20,169,770 shares of common stock, $.001 par value, outstanding as
of July 31, 1999.




                                  FIRST SCIENTIFIC, INC.
                                       FORM 10-QSB


                               QUARTER ENDED JUNE 30, 1999

                                    TABLE OF CONTENTS

                              PART I - FINANCIAL INFORMATION

                                                                       Page

      Item 1.     Financial Statements

              Condensed Consolidated Balance Sheets (Unaudited) -
               June 30, 1999 and December 31, 1998. . . . . . . .    3

              Condensed Consolidated Statements of Operations
               (Unaudited) for the Three Months and Six Months
               Ended June 30, 1999 and 1998 and for the Cumulative
               Period from April 30,
               1990 (Date of Inception) through June 30, 1999 . .     4

              Condensed Consolidated Statements of Cash Flows
               (Unaudited) for the Six Months Ended June 30,
               1999 and 1998 and for the Cumulative Period
               from April 30, 1990 (Date of Inception) through
               June 30, 1999 . . . . . . . . . . . . . . . . . . .    5

              Notes to the Condensed Consolidated Financial
                Statements (Unaudited) . . . . . . . . . . . . . .    6

      Item 2.  Management's Discussion and Analysis and Plan of
                Operation. . . . . . . . . . . . . . . . . . . . .    8


                               PART II - OTHER INFORMATION


      Item 1.  Legal Proceedings . . . . . . . . . . . . . . . . . .  12

      Signatures   . . . . . . . . . . . . . . . . . . . . . . . . .  13



                              PART I - FINANCIAL INFORMATION

      Item 1.     Financial Statements

                          FIRST SCIENTIFIC, INC. AND SUBSIDIARY
                             (A Development Stage Enterprise)
                          CONDENSED CONSOLIDATED BALANCE SHEETS
                                       (UNAUDITED)


                                                     June 30,   December 31,
                                                         1999           1998
                                                 ------------   ------------

                                    ASSETS
      Current Assets
         Cash                                    $    696,736   $  1,286,299
         Investment in securities
           available-for-sale                         116,571        194,784
         Trade receivables                            121,104            614
         Inventory                                     46,863         26,619
         Prepaid expenses                              12,817         29,356
                                                 ------------   ------------

              Total Current Assets                    994,091      1,537,672

      Property and Equipment                          140,089         95,378
          Less: accumulated depreciation              (13,587)        (2,982)
                                                 ------------   ------------
           Net Property and Equipment                 126,502         92,396

      Purchased Technology, Net                        63,750        108,750

      Investment in Equiy Securities, at Cost               -         50,000
                                                 ------------   ------------
      Total Assets                               $  1,184,343   $  1,788,818
                                                 ============   ============


                     LIABILITIES AND STOCKHOLDERS' EQUITY

      Current Liabilities
          Accounts Payble                        $     32,232   $     54,334
          Customer deposits                            33,750         33,750
          Accrued liabilities                          16,678         75,979
          Capital lease obligation -
            current portion                             4,696          2,070
          Related party notes payable                  16,026         22,693
                                                 ------------   ------------
           Total Current Liabilities                  103,382        188,826
                                                 ------------   ------------
      Long-Term Capital Lease Obligation                8,296          4,784
                                                 ------------   ------------
      Stockholders' Equity
          Preferred stock 1,000,000 shares
            authorized, no shares outstanding               -              -

          Common stock $.001 par value,
           50,000,000 shares authorized;
           issued and outstanding: 20,169,770
           shares at June 30, 1999 and
           December 31, 1998                           20,170         20,170
          Additional paid-in-capital                6,429,114      6,429,114
          Unearned compensation                       (53,088)       (84,056)
          Accumulated other comprehensive loss       (135,489)        (7,275)
          Deficit accumulated during the
            development stage                      (5,188,042)    (4,762,745)
                                                 ------------   ------------
              Total Stockholders' Equity            1,072,665      1,595,208
                                                 ------------   ------------

      Total Liabilities and Stockholders'
        Equity                                   $  1,184,343   $  1,788,818
                                                 ============   ============

      The accompanying notes are an integral part of these financial statements.

                                         -3-


                 FIRST SCIENTIFIC, INC. AND SUBSIDIARY
                    (A Development Stage Enterprise)
                 CONSOLIDATED STATEMENTS OF OPERATIONS
                            (UNAUDITED)
<TABLE>
<CAPTION>
                                                                                      Cumulative From
                                                                                       April 30, 1990
                                    For the Three Months      For the Six Months    (Date of Inception)
                                       Ended June 30,            Ended June 30,           Through
                                  ------------------------   -------------------------    June 30,
                                     1999          1998         1999          1998          1999
                                  ----------   -----------   -----------   -----------   -----------
  <S>                            <C>          <C>           <C>           <C>           <C>
  Sales                           $  121,929   $     7,341   $   122,299   $     7,612   $   358,295
  Cost of Sales                       24,049         4,771        24,297         4,879       178,949
                                  ----------   -----------   -----------   -----------   -----------
  Gross Profit                        97,880         2,570        98,002         2,733       179,346
                                  ----------   -----------   -----------   -----------   -----------
  Operating Expenses
      General and administrative
       expense                       240,595        33,288       526,010        48,085     1,363,342
      Research and development
       expense                         9,846         8,013        16,108        12,583     4,005,658
                                  ----------   -----------   -----------   -----------   -----------
       Total Operating Expenses      250,441        41,301       542,118        60,668     5,369,000
                                  ----------   -----------   -----------   -----------   -----------
  Loss from Operations              (152,561)      (38,731)     (444,116)      (57,935)   (5,189,654)

  Other Income and (Expense)
      Interest income                  9,024            -         21,170            -         35,852
      Interest expense                (1,187)       (8,023)       (2,351)      (16,045)      (96,121)
                                  ----------   -----------   -----------   -----------   -----------
  Loss Before Income Taxes          (144,724)      (46,754)     (425,297)      (73,980)   (5,249,923)

  Benefit from Income Taxes               -             -             -             -         61,881
                                  ----------   -----------   -----------   -----------   -----------
  Net Loss                        $ (144,724)  $   (46,754)  $  (425,297)  $   (73,980)  $(5,188,042)
                                  ==========   ===========   ===========   ===========   ===========
  Basic and Diluted Loss Per
   Common Share                   $     (.01)  $     (0.00)  $      (.02)  $      (.01)  $      (.48)
                                  ==========   ===========   ===========   ===========   ===========
  Weighted Average Number of
   Shares Used in Per-Share
   Calculation                    20,169,770    10,467,581    20,169,770    10,467,581    10,845,214
                                  ==========   ===========   ===========   ===========   ===========
<FN>
       The accompanying notes are an integral part of these financial statements.
                                        -4-
</FN>
</TABLE>



                      FIRST SCIENTIFIC, INC. AND SUBSIDIARY
                         (A Development Stage Enterprise)
                 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)

                                                              Cumulative From
                                                               April 30, 1990
                                                                  (Date of
                                           For the Six Months     Inception)
                                             Ended June 30,        Through
                                         -----------------------   June 30,
                                            1999         1998        1999
                                         ----------   ----------  -----------
  Cash Flows From Operating Activities
     Net loss                            $ (425,297)  $ (73,980)  $(5,188,042)
     Adjustments to reconcile net loss
      to net cash used in operating
      activities:
        Depreciation and amortization        55,605          52        84,837
        Common stock issued for services         -           -         74,355
        Common stock issued for purchased
             Research and development            -           -      3,766,440
        Compensation from stock
         options granted                     30,968          -        121,106
        Deferred tax benefit                     -           -        (61,881)
        Changes in operating assets and
          and liabilities:
             Accounts receivable           (120,490)      8,425      (121,104)
             Inventory                      (20,244)     (2,043)      (46,863)
             Prepaid expenses                16,539       2,934       (12,817)
             Accounts payable               (22,102)        671        32,232
             Customer deposits                   -       33,750        33,750
             Accrued liabilities            (59,302)     10,960       149,109
             Deferred compensation               -        2,450            -
                                         ----------   ---------   -----------
       Net Cash Used in Operating
        Activities                         (544,323)    (16,781)   (1,168,878)
                                         ----------   ---------   -----------
  Cash Flows From Investing Activities
       Cash paid for equipment              (40,983)         -       (128,644)
       Cash received from sale of
        securities available-for-sale            -           -        302,847
                                         ----------   ---------   -----------
       Net Cash Provided by (Used in)
        Investing Activities                (40,983)         -        174,203
                                         ----------   ---------   -----------
  Cash Flows From Financing Activities
       Proceeds from borrowing                4,336      11,050       260,311
       Principal payments on notes
        payable                                  -      (15,814)     (155,975)
       Proceeds from loans from
        stockholders                             -       20,030       158,934
       Principal payments on loans
        from stockholder                     (6,667)         -        (70,474)
       Principal payment under capital
        lease obligation                     (1,926)         -         (2,788)
       Proceeds from issuance of
        common stock                             -        6,250     1,501,403
                                         ----------   ---------   -----------
       Net Cash Provided by  Financing
        Activities                           (4,257)     21,516     1,691,411
                                         ----------   ---------   -----------
  Net Increase (Decrease) in Cash          (589,563)      4,735       696,736

  Cash and Cash Equivalents at
   Beginning of Period                    1,286,299       7,938            -
                                         ----------   ---------   -----------
  Cash and Cash Equivalents at
   End of Period                         $  696,736   $  12,673   $   696,736
                                         ==========   =========   ===========

   The accompanying notes are an integral part of these financial statements.
                                   -5-


               FIRST SCIENTIFIC, INC. AND SUBSIDIARY
       NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                            (UNAUDITED)

  NOTE 1-SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

  Interim Condensed Financial Statements-The accompanying
  condensed consolidated financial statements are unaudited.
  In the opinion of management, all necessary adjustments
  (which include only normal recurring adjustments) have been
  made to present fairly the financial position, results of
  operations and cash flows for the periods presented.
  Certain information and note disclosures normally included
  in financial statements prepared in accordance with
  generally accepted accounting principles have been
  condensed or omitted. It is suggested that these condensed
  consolidated financial statements be read in conjunction
  with the First Scientific financial statements and notes
  thereto included in the Form 10-KSB dated December 31,
  1998. The results of operations for the six month period
  ended June 30, 1999 are not necessarily indicative of the
  operating results to be expected for the full year.

  Principles of Consolidation - The accompanying condensed
  consolidated financial statements include the accounts and
  transactions of First Scientific Corporation for all
  periods presented and the accounts and transactions of
  First Scientific, Inc. from September 15, 1998 .
  Intercompany accounts and transactions have been eliminated
  in consolidation. The consolidated entities are
  collectively referred to herein as "First Scientific."

  NOTE 2-INVESTMENT IN SECURITIES AVAILABLE-FOR-SALE

  Changes in investments in securities available-for-sale
  were as follows:

            Balance - December 31, 1998             $ 194,784
            Reclassification from investment
             in equity securities at cost for
             expiration of restriction                 50,000
            Unrealized loss on securities
             available-for-sale                      (128,213)
                                                    ---------
            Balance - June 30, 1999                 $ 116,571


  NOTE 3-COMPREHENSIVE LOSS

  Other comprehensive loss of  First Scientific consists of
  an unrealized loss on investment in securities
  available-for-sale. Comprehensive loss is computed as follows:

  <TABLE>
  <CAPTION>
                                                                                 Cumulative from
                                                                                  April 30, 1990
                                                                                     (Date of
                                      For the Three Months    For the Six Months     Inception)
                                          Ended June 30,        Ended June 30,        Through
                                     ----------------------  ----------------------   June 30,
                                        1999        1998        1999        1998        1999
                                     ----------  ----------  ----------  ----------  -----------
 <S>                                <C>         <C>         <C>         <C>         <C>
  Net Loss                           $ (144,724) $  (46,754) $ (425,298) $  (73,980) $(5,188,042)

  Other Comprehensive Loss
    Unrealized loss on investment in
     securities available-for-sale      (77,714)         -     (128,213)         -      (135,488)
                                     ----------  ----------  ----------  ----------  -----------
  Comprehensive Loss                 $ (222,438) $  (46,754) $ (553,511) $  (73,980) $(5,323,530)
                                     ==========  ==========  ==========  ==========  ===========
 </TABLE>


               FIRST SCIENTIFIC, INC. AND SUBSIDIARY
       NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                            (UNAUDITED)


  NOTE 4-SUPPLEMENTAL CASH FLOW INFORMATION

  Interest paid during the six months ended June 30, 1999 and
  1998, was $2,351 and $16,045, respectively, and $96,121 for
  the period from April 30, 1990 (date of inception) through
  June 30, 1999.  During 2nd quarter 1999 First Scientific
  acquired computer equipment with a fair market value of
  $3,727 and incurred a capital lease obligation of $3,727.

  NOTE 5 - COMMITMENTS AND CONTINGENCIES

  Capital Lease -  During the first six months of 1999, First
  Scientific entered into two capital lease agreements for
  computer equipment.  The first lease agreement is for a
  3-year term requiring monthly payments of $177 and a
  present value of $4,336 at inception of the lease.  The
  second agreement is for a 3-year term requiring monthly
  payments of $150 and a present value of $3,727.

  Unasserted Claim - On January 5, 1999 First Scientific was
  advised of a claim against it allegedly arising out of an
  Agreement in Principle made in 1991 (the "1991 Agreement")
  by Linco Industries, Inc. ("Linco" now known as First
  Scientific Corporation, a wholly owned subsidiary or First
  Scientific, Inc.). The 1991 Agreement purported to promise
  shares of Linco common stock to an individual (the
  Claimant)  if certain conditions were met by the Claimant
  in representing Linco to potential customers.  As of June
  30,1999 no legal proceeding has been filed with respect to
  this claim by the Claimant, nor has First Scientific made
  any settlement offer in an attempt to resolve the matter.
  First Scientific's management maintains that the 1991
  Agreement is no longer valid because the conditions in the
  1991 Agreement were not met in a reasonable time and
  because of the  failure of other material terms.

       Additionally, an indemnification agreement in favor of
  First Scientific by the former founding Linco shareholders
  requires the latter to satisfy any obligations Linco may
  have incurred prior to the reorganization. Consequently,
  First Scientific would require that any eventual settlement
  or award resulting from the 1991 Agreement be satisfied
  entirely by the founding shareholders of Linco.  The Linco
  founders have assured First Scientific that they will
  defend this matter in the event any legal proceedings
  should be filed against First Scientific.  During the
  quarter ended June 30, 1999, the Claimant has  persisted in
  his claim.  Subsequent to the end of the reporting quarter,
  June 30, 1999, in response to the Claimant's demands, the
  Linco founders filed with the District Court of Weber
  County, State of Utah (Civil Case No. 99090484) an action,
  including First Scientific, Inc., First Scientific
  Corporation, and Linco Industries, Inc as co-Plaintiffs,
  for declaratory judgement that the Claimant (the Defendant
  in said action) has no entitlement against any of the
  Plaintiffs, including First Scientific.  The Claimant has
  recently been served, but has not yet responded to the
  complaint in this action.

       Item 2.  Managements's Discussion and Analysis and
  Plan of Operation.

       The following discussion and analysis provides
  information which management believes is relevant to an
  assessment and understanding of First Scientific's
  consolidated results of operations and financial condition.
   The discussion should be read in conjunction with the
  unaudited condensed consolidated financial statement, as of
  June 30, 1999, together with the annual financial
  statements as of December 31,1998.  Whenever in this
  discussion the term "First Scientific" is used, it should
  be understood to refer to First Scientific, Inc. and its
  wholly owned subsidiary on a consolidated basis, except
  where the context clearly indicates otherwise.

  Plan of Operation

       First Scientific is a development stage company which,
  since inception, has incurred losses from operations. As of
  June 30, 1999, the cumulative net losses of First
  Scientific since inception total $5,188,042 of which
  $3,766,440 is attributable to a non-recurring charge for
  acquired research and development, as described in First
  Scientific's annual report on Form 10-KSB dated December
  31, 1998. First Scientific is engaged primarily in the
  development of chemical formulations that management feels
  will have worldwide sales opportunities.  First Scientific
  has had no significant sales from its products but intends
  to initially market its products through private label
  relationships with companies that are major distributors in
  the medical, healthcare, over-the-counter, and multi-level
  arenas.  Development of First Scientific's own brands, may
  also be sold through regional distributors, especially in
  medical markets, and will only be pursued on a case-by-case
  basis as profitable opportunities are identified and
  evaluated.

       First Scientific has developed two unique
  formulations. The first is a moisturizing, antimicrobial
  sanitizing formulation that removes 99.99% of bacteria from
  the skin without the harsh effects of alcohol, CHG, PCMX,
  triclosan, or iodine (this product can be delivered in
  wipe, spray, lotion or soap forms).  The second is a
  topical rash prevention and treatment formulation that
  cleanses and moisturizes the skin.  It is used for
  treatment against skin rashes caused by incontinence as
  well as other skin rashes (in wipe form).

       The potential worldwide market for products similar to
  First Scientific's has grown significantly in recent years
  and is projected to continue growing at a substantial rate.
   Regarding growth of the market for products similar to
  First Scientific's antimicrobial formulation, the growth in
  demand is due to the increase in bacteria related disease,
  sickness and death from methicillin-resistant and other
  bacteria, the demands of government and healthcare
  agencies/providers to create healthier treatment
  environments and the insistence of the public in general
  for healthier living and working conditions.  The potential
  market growth for products similar to First Scientific's
  rash formulation is primarily a function of the growth
  rates in the  incontinent geriatric population, as baby
  boomers grow older.  The product appears to also have
  application in the infant care market.  Management believes
  the markets for products similar to First Scientific's
  products will continue to expand and that the potential of
  First Scientific to become a significant participant  in
  such markets is a reasonable expectation.

       First Scientific currently outsources manufacturing of
  its products. First Scientific has developed relationships
  with manufacturers, and is in the process of qualifying
  other manufacturers, who have U.S. Food and Drug
  Administration ("F.D.A.") approved facilities and
  experience manufacturing in accordance with F.D.A.
  standards. These companies are generally in the business of
  manufacturing for various customers who require F.D.A.
  compliant facilities for their products.  First Scientific
  is able to produce a concentrate of its antimicrobial
  formulation at its own facility, or at contract facilities,
  under F.D.A. protocols. The concentrate can then be shipped
  to its contract manufacturers for production runs according
   to  customer specifications.  This procedure helps protect
  the trade secret status of this proprietary formulation.
  However, First Scientific does not use this same
  concentrate mixing procedure in the production of its
  dimethicone-based rash prevention and treatment
  formulation, because currently First Scientific cannot
  economically mix concentrate itself for this product.
  Strict confidentiality agreements are in place with the
  manufacturer to protect the trade secret status of this
  product formulation.

       The cash requirements of First Scientific through the
  end of first quarter 2000  will vary based upon a number of
  factors including, but not limited to, continuing research
  and development levels, market development, facilities
  enhancement, additional personnel, travel and other
  expenses related to projected growth. With the new business
  First Scientific is now negotiating, management believes
  that existing cash, cash equivalents and cash generated
  from anticipated sales will be sufficient to meet the
  obligations of First Scientific over the next  nine
  months. However, in light of management's cash consumption
  projections for this period, if anticipated sales do not
  materialize in a timely manner at projected volumes, First
  Scientific would likely need a bank line of credit and/or
  additional equity funding to meet its working capital needs
  by the end of the first quarter of 2000. There is no
  assurance that any funding will be available or that, if
  available, the terms of such funding will be favorable to
  First Scientific.

       A new source of revenue has developed for First
  Scientific.  A major division of a large multinational drug
  company recently engaged First Scientific, on a fee for
  service basis, to perform testing procedures that fulfill
  FDA compliance requirements relating to potential product
  sales to this customer.  Initial responses from this
  customer were favorable regarding First Scientific's
  testing procedures and operating protocols.  Actual testing
  for this customer began during the quarter ended June 30,
  1999.  The prospects for ongoing testing work with this
  customer appear likely. This relationship has allowed First
  Scientific to gain experience and to develop standard
  operating procedures that satisfy, not only this customer's
  needs, but that should withstand the most critical
  evaluations and requirements of future customers, and
  therefore, may provide new revenue opportunities.

       Product research and development is an ongoing process
  at First Scientific.  Existing products are continuously
  being refined to meet the needs of markets being pursued.
  Potential customers have presented product specification
  requests from time to time which were different from those
  of First Scientific's existing product specifications.
  These circumstances caused additional research and
  development to be performed in order to meet the required
  specifications.  Similar requests from potential customers
  are also anticipated in the future.   First Scientific
  likewise researches new products that fall within the scope
  of its currently defined market place and new market places
  that appear to have future economic potential.

       In light of First Scientific's current mode of
  operations of outsourcing its manufacturing, existing plant
  and equipment are projected to be sufficient to meet most
  of its growth needs.  However, should First Scientific
  decide, or be required, to perform expanded testing for its
  clients and/or should it undertake in-house manufacturing,
  additional capital would be required to fund the
  establishment of such activities.

       First Scientific now employs 10 individuals in
  management, administrative, and technical positions. As
  First Scientific continues to grow, additional personnel
  will need to be added to enable the Company to meet its
  projections. A Vice President of Sales and Marketing was
  added to the Company's management team during the quarter
  ended June 30, 1999, as were an executive secretary and one
  lab technician.  These  hires represent a forty-three
  percent increase in First Scientific's workforce.
  Management also plans to add a lab testing/quality control
  manager and another lab technician by year end.

  Management's Discussion and Analysis of Financial Condition
  and Results of Operations

  Financial Position

       First Scientific had $696,736 in cash as of June 30,
  1999. This represents a decrease of  $589,563 from December
  31, 1998. Working capital, as of June 30,1999, decreased to
  $890,709 compared to working capital of $1,348,846 at
  December 31, 1998.

  Results of Operations

       During the three months and six months ended June 30,
  1999, the First Scientific had total operating revenues of
  $121,929 and $122,299 respectively, compared with total
  operating revenues of $7,341 and $7,612 for the comparable
  periods from the prior year.  Revenue for 1999 has
  primarily resulted from contracts to test products for
  customers.

       Prior to December 1998 Company revenues were generated
  from sporadic sales of a Linseed oil based soap product and
  a rash prevention product created for a distributor who
  sells this product under private labels to an
  over-the-counter customer. First Scientific has decided to
  discontinue the sale of these products, but does expect
  minimal revenue as existing inventory is liquidated.  In
  June 1998, First Scientific entered into a private label
  supply agreement with a multinational distributer of
  medical and healthcare products.  This agreement was for
  individual antimicrobial wipes that  the customer had
  planned to export, however, based on the latest
  communications with this customer, it is doubtful the
  manufacture of this product will ever take place or that
  any future business will materialize.

       Ongoing negotiations with a major division of a
  Fortune 100 company for a dimethicone wipe product have not
  formally concluded, but a letter of intent and
  manufacturer's purchase order have been received by First
  Scientific. Management believes a  significant contract
  will be signed with this customer during the  third quarter
  of 1999 which will immediately begin to recognize  revenue.
  Testing revenue from this company, regarding F.D.A.
  compliance, began during the quarter ended June 30, 1999
  and accounted for the majority of the revenue during the
  quarter. Negotiations with two other large domestic private
  labelers began during the reporting quarter which could
  lead to orders being placed during the third or fourth
  quarters of 1999. First Scientific also concluded a
  regional distribution agreement with Welmed Specialties
  during the quarter ended June 30, 1999 which should begin
  to generate revenue during the fourth quarter of 1999.
  This agreement covers  six western states; California,
  Nevada, Oregon, Washington, Utah and Hawaii. Welmed will
  have non-exclusive distribution rights to First
  Scientific's products in these states and exclusive rights
  to First Scientific's Fresh Cleanse(R) brand products to
  hospitals, nursing homes, medical clinics and doctors
  offices in this territory. Should anticipated sales from
  customers with whom First Scientific has agreements in
  place or is  negotiating or other potential sales
  opportunities which First Scientific anticipates
  materializing, not come to fruition, the ability of First
  Scientific to sustain operations into the second quarter of
  2000, without additional debt or equity financing, would be
  questionable.

       Private label agreements, such as those discussed
  above, create certain risks for First Scientific.  These
  risks include (i) reliance for sales of products on other
  parties, and therefore reliance on the other parties'
  marketing ability, marketing plans and credit-worthiness;
  (ii) if First Scientific's products are marketed under
  other parties' labels, goodwill associated with use of the
  products generally inures to the benefit of the other
  parties rather than First Scientific; (iii) First
  Scientific may have only limited protection from changes in
  manufacturing costs and raw material costs; and (iv) if
  First Scientific continues to rely on other parties for all
  or substantially all of its sales, First Scientific may be
  limited in its ability to negotiate with such other parties
  upon eventual renewals of their agreements.  It is the
  belief of management that these risks are mitigated by
  initial market demands, the apparent uniqueness of the
  Company's formulations, large existing and expanding
  markets  for its products and  the caliber of customers
  with which it is  currently negotiating.  However, First
  Scientific recognizes that, in the short run, it will be
  dependent on a few large customers where the bulk of its
  sales are envisioned to be generated.  Until a broader base
  of customers has been established, the loss  one such
  customer could have a serious material adverse impact on
  the operating viability of First Scientific.

       First Scientific uses as many as twenty specific
  chemical and botanical ingredients to formulate each of its
  products. In most cases, supplies of  ingredients for
  First Scientific's formulations continues to remain readily
  available from multiple sources.  First Scientific
  continues to maintain very good relationships with its
  suppliers and does not anticipate problems that would cause
  significant interruption, delay or availability of such
  ingredients.

       General and administrative expenses were $240,595 and
  $526,011 for the three months and six months ended June 30,
  1999, respectively, compared with $33,288 and $48,085 for
  the comparable periods from the prior year. The increase in
  expenditures between the 1999 and 1998 periods was due to
  the continued transition of First Scientific  from a
  one-man product development entity, with minimal sales
  during the second quarter of 1998, to an adequately staffed
  operation, in the second quarter of 1999, capable of
  administrating anticipated growth.  Executive office
  space into which First Scientific moved during 1998 should
  meet growth needs for the foreseeable future.

       Research and development expenses were $9,846 and
  $16,108 for the three and six months ended June 30, 1999,
  respectively, compared with $8,013 and $12,583 for the
  comparable periods from the prior year. The increase in
  expenditures between the 1999 and 1998 periods resulted
  from the continued refinement of First Scientific's
  formulations and the development of new product variations
  to meet customer request. Management anticipates an
  increase in research and development expenses for future
  periods, as First Scientific expands its product offerings.

  Liquidity and Capital Resources

       Historically, First Scientific has financed its
  operations principally through  loans, private placements
  of equity securities and sporadic product sales.  During
  the six month period, ending June 30, 1999, sales
  constituted the source of the majority of funds from the
  operations of First Scientific.  First Scientific used net
  cash of $544,323 in operating activities during the six
  months ended June 30, 1999. As of June 30, 1999, First
  Scientific's liabilities totaled $111,678. The Company had
  working capital of $890,709 as of June 30,1999.

  Year 2000

       First Scientific uses computers principally for
  scientific modeling and calculation, product/market
  research  and administrative functions such as
  communications, word processing, accounting and management
  and financial reporting. First Scientific's computer system
  was purchased September, 1998. The software utilized by
  First Scientific is generally standard "off the shelf"
  software, typically available from a number of vendors.
  While First Scientific believes it has taken all
  appropriate steps to assure year 2000 compliance, the
  Company is substantially dependent on vendor compliance.
  Even if vendor assurances that First Scientific's systems
  are 2000 compliant be incorrect, management believes
  systems failures would not have a material adverse impact
  on its operations.

       In addition to its own computer systems, in connection
  with its business activities, First Scientific interacts
  with suppliers, customers, creditors and financial service
  organizations domestically and globally who use computer
  systems. It is impossible for First Scientific to monitor
  all such systems, and there can be no assurance that the
  failure of such systems would not have a material adverse
  impact on First Scientific's business and operations.  The
  Company continues to evaluate what contingency plans it may
  adopt in order to make in the event First Scientific or
  parties with whom it does business experience year 2000
  problems.

  Forward-Looking Statements

       When used in this Form 10-Q and in other filings by
  First Scientific with the SEC, in First Scientific's press
  releases or other public or stockholder communications, or
  in oral statements made with the approval of an authorized
  executive officer of First Scientific, the words or phrases
  "would be," "will allow," "intends to," "will likely
  result," "are expected to," "will continue," "is
  anticipated," "estimate," "project," or similar expressions
  are intended to identify "forward-looking statements"
  within the meaning of the Private Securities Litigation
  Reform Act of 1995.

       First Scientific cautions readers not to place undue
  reliance on any forward-looking statements, which speak
  only as of the date made, are based on certain assumptions
  and expectations which may or may not be valid or actually
  occur, and which involve various risks and uncertainties,
  including but not limited to risk of product demand,
  market acceptance, economic conditions, competitive
  products and pricing, difficulties in product development,
  commercialization, and technology, and other risks. In
  addition, sales and other revenues may not commence and/or
  continue as anticipated due to delays or otherwise. As a
  result, First Scientific's actual results for future
  periods could differ materially from those anticipated or
  projected.

       Unless otherwise required by applicable law, First
  Scientific does not undertake, and specifically disclaims
  any obligation, to update any forward-looking statements to
  reflect occurrences, developments, unanticipated events or
  circumstances after the date of such statements.


                  PART II - OTHER INFORMATION

  Item 1.  Legal Proceedings.

       First Scientific is not involved in, nor has it been
  involved as a defendant in, any legal proceedings as of the
  end of the reporting quarter, June 30, 1999.  However, on
  January 5, 1999 First Scientific was advised of a claim
  against it allegedly arising out of an Agreement in
  Principle made in 1991 (the "1991 Agreement") by Linco
  Industries, Inc. ("Linco" now known as First Scientific
  Corporation, a wholly owned subsidiary or First Scientific,
  Inc.). The 1991 Agreement purported to promise shares of
  Linco common stock to an individual (the Claimant)  if
  certain conditions were met by the Claimant in representing
  Linco to potential customers.  As of June 30,1999 no legal
  proceeding has been filed with respect to this claim by the
  Claimant, nor has First Scientific made any settlement
  offer in an attempt to resolve the matter.  First
  Scientific's management maintains that the 1991 Agreement
  is no longer valid because the conditions in the 1991
  Agreement were not met in a reasonable time and because of
  the  failure of other material terms.

       Additionally, an indemnification agreement in favor of
  First Scientific by the former founding Linco shareholders
  requires the latter to satisfy any obligations Linco may
  have incurred prior to the reorganization. Consequently,
  First Scientific would require that any eventual settlement
  or award resulting from the 1991 Agreement be satisfied
  entirely by the founding shareholders of Linco.  The Linco
  founders have assured First Scientific that they will
  defend this matter in the event any legal proceedings
  should be filed against First Scientific.  During the
  quarter ended June 30, 1999, the Claimant has  persisted in
  his claim.  Subsequent to the end of the reporting quarter,
  June 30, 1999, in response to the Claimant's demands, the
  Linco founders filed with the District Court of Weber
  County, State of Utah (Civil Case No. 99090484) an action,
  including First Scientific, Inc., First Scientific
  Corporation, and Linco Industries, Inc as co-Plaintiffs,
  for declaratory judgement that the Claimant (the Defendant
  in said action) has no entitlement against any of the
  Plaintiffs, including First Scientific.  The Claimant has
  recently been served, but has not yet responded to the
  complaint in this action.


                            SIGNATURES


  Pursuant to the requirements of the Securities and Exchange
  Act of 1934, the Registrant has duly caused this report to
  be signed on its behalf by the undersigned thereunto duly
  authorized.

                            REGISTRANT

                      FIRST SCIENTIFIC, INC.
                            Registrant


  DATED:  August 4, 1999             By:  /s/ Douglas R. Warren
                                        -----------------------
                                        Douglas R. Warren, President


  DATED:  August 4, 1999             By: /s/ Gordon M. Davis
                                        -----------------------
                                        Gordon M. Davis, Vice President
                                        Administration/CFO (Principal
                                        Financial and Accounting Officer)